Axsome Therapeutics Inc (19X)

Currency in EUR
87.24
+0.60(+0.69%)
Delayed Data·
19X is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
86.3287.76
52 wk Range
62.00135.00
Key Statistics
Bid/Ask
86.56 / 87.08
Prev. Close
86.64
Open
86.32
Day's Range
86.32-87.76
52 wk Range
62-135
Volume
167
Average Volume (3m)
337
1-Year Change
7.86%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
19X Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Axsome Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Axsome Therapeutics Inc Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

Compare 19X to Peers and Sector

Metrics to compare
19X
Peers
Sector
Relationship
P/E Ratio
0.0x−0.1x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x3.0x2.6x
Price / LTM Sales
0.0x1.8x3.2x
Upside (Analyst Target)
0.0%112.2%41.2%
Fair Value Upside
Unlock28.6%6.2%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

19X Income Statement

People Also Watch

141.56
FI
+1.16%
111.41
CRWV
+1.02%
52.120
ASTS
-3.87%
17.980
QBTS
-2.02%

FAQ

What Stock Exchange Does Axsome Therapeutics Inc Trade On?

Axsome Therapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Axsome Therapeutics Inc?

The stock symbol for Axsome Therapeutics Inc is "19X."

What Is the Axsome Therapeutics Inc Market Cap?

As of today, Axsome Therapeutics Inc market cap is 4.29B.

What Is Axsome Therapeutics Inc's Earnings Per Share (TTM)?

The Axsome Therapeutics Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 19X a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Axsome Therapeutics Inc Stock Split?

Axsome Therapeutics Inc has split 0 times.

What is the current trading status of Axsome Therapeutics Inc (19X)?

As of 29 Jul 2025, Axsome Therapeutics Inc (19X) is trading at a price of 87.24, with a previous close of 86.64. The stock has fluctuated within a day range of 86.32 to 87.76, while its 52-week range spans from 62.00 to 135.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.